PHAXIAM Management Team

Thibaut du Fayet brings to the Company over 20 years of experience in the pharmaceutical and life sciences industry. After obtaining an MBA from ESSEC Business School in 1992, he was Senior Managing Director at Bossard-Gemini for six years. From 2000, he held management positions first at Rhône Poulenc as Strategy Director for four years, and then at BioMerieux where he was also Strategic Marketing Director for four years. In 2008, he joined Transgene where he held the position of VP Corporate Development, Alliances & Programs Management for 13 years, within the Management leadership team. Through his various leadership roles in development, strategy, business development, and program management, he has acquired important and diverse skills in the pharmaceutical industry.

Céline Breda began her career at Sanofi Pasteur in France and the United States. In 2005, she joined the biotech company Valneva, where she headed up pharmaceutical operations for over eight years. Following the sale of Valneva’s bioproduction site in Nantes in 2013, she took over the Operations Management of this unit, initially for the company BE Vaccines, a subsidiary of the Indian pharmaceutical group Biological E, and then, from 2019, for the company Naobios, a subsidiary of CDMO Clean Biologics. She joined Pherecydes Pharma in 2021 as CMC Director.

Eric joined Erytech in 2015. Eric Soyer has a more than 20 year experience in Management positions in financial and operational fields in public or private companies including eight years as Chief Financial Officer of EDAP TMS S.A., and Managing Director of the French affiliate Chief Financial Officer for a company operating nursing homes and post-care clinics, Financial and legal director for an insurance services company. He started his career as a financial controller and cost accountant for Michelin Group. Eric Soyer graduated from the ESC Clermont School of Management (France) and holds an M.B.A. from the University of Kansas and an Executive M.B.A. from the HEC Paris School of Management (France).

Karine joined Erytech Pharma in September 2017, leading Business Development & Licensing to support the strategic development of products,  establish collaborative partnership programs, licensing agreements, and drive competitive intelligence. She was appointed Director of Innovation and Valorization in 2022. In this role, she manages Erytech’s preclinical R&D team, external innovation and business development activities, before becoming Chief Business Officer following the merger in June 2023. With a PhD in Molecular and Cellular Biology, she began her career as a researcher in charge of R&D programs in the non-profit company Généthon (France), dedicated to the development of gene therapies for rare diseases, where she gained in-depth experience of innovative product development in the field of gene therapy. She then moved to the scientific Direction of AFM-Téléthon to support the detection, valorization and support of innovative projects to be funded in the field of rare diseases. 

Dr. Pascal Birman has 30 years of experience in medical research and pharmaceutical development, particularly in endocrinology and metabolic diseases. After a career as a physician at the AP-HP (1981-1990), he joined the Servier Group as Head of International Projects, and then held the executive positions of Director of Therapeutic Research and Clinical Operations Director for Europe and Asia. In 2004, Dr. Birman joined the pharmaceutical company Ipsen where he worked for 13 years in several key positions until becoming Vice President of Global Clinical Development Programs.

Frédérique gained initial experience in a clinical and research environment before moving into the pharma/biotech companies. There, she drew upon her background as a pharmacist and Engineer in Biotechnology to manage production first and then development over ten years (MSD Chibret, then Europhartech).

Subsequently, she filled the position of Head of QA/QP Deputy, including the regulatory unit, in CARBOGEN AMCIS. Afterward, she was chosen to design and implement the quality system in 4D Pharma, managing as well IMPD submissions.

She founded 5QBD-Biotech, a Quality and Regulatory consultancy company, applying QbD and Lean approaches and guiding small biotechs on regulatory strategies (LBPs, ATMPs…).

In 2020, she became Quality & Regulatory Affairs Director at Pherecydes Pharma, liaising with cross-functionalteams on the clinical development of bacteriophages, including the in vitro diagnostic test (Phagogram) development. 

Jérôme Bailly, Pharm.D. has served as our Qualified Person since December 2011, and has served as our Director of Pharmaceutical Operations since 2007. Prior to 2007, he was the Director of QA/Production at Skyepharma and Laboratoire Aguettant. Dr. Bailly holds a Pharm.D. and a degree in Chemica Engineering, specializing in Biopharmaceutical Engineering and Cellular Production from École Polytechnique de Montréal (Canada).

Cindy is a microbiologist, expert in bacteriology. She obtained a PhD at the Pasteur Institute (Paris) in the antibiotic resistance, virulence and genetic diversity of Klebsiella. She has also worked on other major pathogens in human clinical practice, such as listeria and staphylococcus aureus.Prior to joining PHAXIAM Therapeutics, Cindy developed new phage display methods and acquired substantial knowledge of bacteriophage biology and genomics. Her international experience (UMC Utrecht, Netherlands) has led her to manage R&D collaborations with industrial potential.